BridgeBio Pharma, Inc. (BBIO)
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BridgeBio Pharma, Inc.
NASDAQ:BBIOHealthcare · Biotechnology
+5.97%$74.95
AH$74.47-0.64%vs close
Mkt Cap$14.6B
Float160.36M
O/S194.8M
Vol
$ Vol
RVOL
Inst Own99.3%
Earnings
Dilution
Financials Summary
Revenue$502.08M
Net Income-$729.31M
Total Assets$936.02M
Free Cash Flow-$447.01M
Debt & Equity
Debt 418%
Total Debt$2.73B
Total Equity-$2.08B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in BBIO's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$936.02M
Liabilities$3.01B
Accounts Receivable$139.44M
Accounts Payable$36.23M
Inventory$26.75M
PP&E (Net)$13.52M
Goodwill$0
Intangible Assets$28.08M
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $502.08M | $221.9M | $9.3M | $77.65M | $69.72M | $8.25M | $40.56M | $0 | $0 |
| YoY Growth | 126.3% | 2285.3% | -88.0% | 11.4% | 745.1% | -79.7% | - | - | - |
| Cost of Revenue | $28.27M | $3.88M | $2.45M | $3.43M | $3.11M | $0 | $2.5M | $0 | $260K |
| Gross Profit | $473.81M | $218.02M | $6.86M | $74.21M | $66.6M | $8.25M | $38.06M | $0 | -$260K |
| Gross Margin | 94.4% | 98.3% | 73.7% | 95.6% | 95.5% | 100.0% | 93.8% | - | - |
| Research and Development | $477.54M | $506.46M | $455.71M | $399.46M | $451.02M | $337.05M | $209.95M | $140.07M | $30.56M |
| Selling, General, and Administrative | $555.14M | $288.93M | $150.59M | $143.19M | $192.21M | $145.68M | $94.35M | $43.59M | $13.3M |
| Other | $10.22M | $15.61M | $7.93M | $43.77M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $1.04B | $811M | $614.23M | $586.42M | $643.23M | $482.73M | $304.3M | $183.66M | $43.86M |
| Operating Income (EBIT) | -$569.09M | -$592.97M | -$607.37M | -$512.2M | -$576.63M | -$474.48M | -$266.24M | -$183.66M | -$43.86M |
| Operating Margin | -113.3% | -267.2% | -6528.8% | -659.6% | -827.1% | -5752.0% | -656.4% | - | - |
| Interest Expense | $53.1M | $99.29M | $81.29M | $80.44M | $46.78M | $36.66M | $8.77M | $2.55M | $13K |
| Interest Income | $19.85M | $17.25M | $18.04M | $7.54M | $1.13M | $4.01M | $8.91M | $2M | $39K |
| Other Income (Expense) | -$165.9M | $50.78M | -$45.88M | $27.55M | -$9.82M | -$31.01M | -$22.34M | $14.21M | $26K |
| Income Before Tax (EBT) | -$734.99M | -$542.19M | -$653.25M | -$484.65M | -$586.45M | -$505.49M | -$288.58M | -$169.45M | -$43.83M |
| Income Tax Expense | $555K | $1.15M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$729.31M | -$535.76M | -$643.2M | -$481.18M | -$562.54M | -$448.72M | -$260.44M | -$130.75M | -$30.57M |
| Net Income Margin | -145.3% | -241.4% | -6913.9% | -619.7% | -806.9% | -5439.7% | -642.1% | - | - |
| Supplementary Data | |||||||||
| EPS | -3.79 | -2.88 | -3.95 | -3.35 | -3.90 | -4.10 | -2.48 | -1.42 | -0.33 |
| Diluted EPS | -3.79 | -2.88 | -3.95 | -3.35 | -3.90 | -4.10 | -2.48 | -1.42 | -0.33 |
| Weighted Average OS | 197.24M | 186.08M | 162.79M | 147.47M | 144.36M | 118.00M | 105.10M | 92.33M | 92.33M |
| EBITDA | -$676.45M | -$436.83M | -$565.47M | -$397.44M | -$533.83M | -$467.38M | -$278.96M | -$183.41M | -$43.56M |
| EBITDA Margin | -134.7% | -196.9% | -6078.3% | -511.9% | -765.7% | -5665.9% | -687.8% | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $570.12M | $681.1M | $375.94M | $376.69M | $393.77M | $356.08M | $363.77M | $436.09M | $92M |
| Short-Term Investments | $17.36M | $0 | $58.95M | $95.23M | $442.89M | $251.01M | $182.22M | $0 | $0 |
| Cash and Short-Term Investments | $587.48M | $681.1M | $434.88M | $471.92M | $836.66M | $607.09M | $545.99M | $436.09M | $92M |
| Accounts Receivable | $139.44M | $4.72M | $1.75M | $17.08M | $19.75M | $0 | $2.85M | $0 | $0 |
| Inventory | $26.75M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $3.83M | $27.65M | $37.93M | $177K | $139K | $0 | $0 | $889K |
| Total Current Assets | $753.68M | $720.69M | $477.59M | $548.85M | $888.86M | $642.82M | $568.62M | $445.22M | $97.13M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $13.52M | $12.78M | $19.84M | $25.25M | $45.97M | $36.83M | $5.63M | $1.57M | $440K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $28.08M | $23.93M | $26.32M | $28.71M | $44.93M | $0 | $0 | $0 | $0 |
| Long-Term Investments | $81.44M | $143.75M | $3.74M | $2.87M | $2.42M | $0 | $31.14M | $17.05M | $381K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | -$81.44M | $18.2M | $18.88M | $17.36M | $30.61M | $23.93M | $26.29M | $1.09M | $92K |
| Total Long-Term Assets | $41.59M | $198.65M | $68.79M | $74.18M | $123.93M | $60.76M | $63.06M | $19.72M | $913K |
| Other Assets | $140.75M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $936.02M | $919.34M | $546.38M | $623.04M | $1.01B | $703.59M | $631.68M | $464.94M | $98.04M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $36.23M | $9.62M | $10.65M | $11.56M | $11.88M | $8.95M | $8.85M | $13.51M | $1.89M |
| Short-Term Debt | $17.41M | $0 | $0 | $0 | $0 | $1.46M | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $20.27M | $0 | $6.1M | $8.16M | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $214.06M | $16.2M | $65.59M | $31.26M | $37.04M | $9.55M | $25.39M | $4.01M | $997K |
| Total Current Liabilities | $287.97M | $154.4M | $143.84M | $121.43M | $135.07M | $95.65M | $60.38M | $32.58M | $8.55M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $2.71B | $1.72B | $1.73B | $1.71B | $1.7B | $475.86M | $91.79M | $54.51M | $143.87M |
| Long-Term Unearned Revenue | $13.08M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $244K | $496.47M | $9.36M | $26.64M | $22.07M | $9.52M | $3.53M | $479.36M | $312K |
| Total Long-Term Liabilities | $2.72B | $2.22B | $1.75B | $1.75B | $1.74B | $500.05M | $95.32M | $533.87M | $144.18M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.7M | $155.7M | $566.44M | $152.73M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $833K |
| Common Stock | $202K | $196K | $181K | $157K | $154K | $125K | $124K | $6.59M | $3.41M |
| Retained Earnings | -$3.82B | -$3.1B | -$2.56B | -$1.92B | -$1.44B | -$888.75M | -$440.03M | -$170.58M | -$61.43M |
| Comprehensive Income & Other | $12K | $8K | $31K | -$328K | -$132K | $192K | $254K | -$231K | -$27K |
| Other Stockholders' Equity | $1.74B | $1.63B | $1.21B | $663.38M | $566.4M | $946.54M | $848.36M | $0 | $0 |
| Total Equity | -$2.08B | -$1.47B | -$1.35B | -$1.25B | -$870.41M | $57.91M | $408.45M | -$163.99M | -$58.02M |
| Minority Interest | -$570K | $10.29M | $11.72M | $9.69M | $4.83M | $49.98M | $67.52M | $62.48M | $3.33M |
| Total Liabilities and Equity | $936.02M | $909.05M | $534.66M | $613.34M | $1.01B | $653.61M | $564.16M | $402.46M | $94.71M |
| Supplementary Data | |||||||||
| Total Debt | $2.73B | $1.73B | $1.74B | $1.72B | $1.73B | $495.79M | $91.79M | $54.51M | $143.87M |
| Net Debt | $2.16B | $1.05B | $1.36B | $1.35B | $1.33B | $139.71M | -$271.98M | -$381.58M | $51.87M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$724.93M | -$543.35M | -$643.2M | -$484.65M | -$586.45M | -$505.49M | -$288.58M | -$169.45M | -$43.83M |
| Depreciation & Amortization | $5.43M | $6.08M | $6.49M | $6.77M | $5.84M | $1.46M | $859K | $245K | $260K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | -$30.93M | -$1.87M | -$859K | -$14.89M | -$260K |
| Stock-Based Compensation | $133.02M | $95.8M | $0 | $91.56M | $99.5M | $58.46M | $21.37M | $6.07M | $1.84M |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | -$134.72M | -$2.97M | $15.33M | $15.17M | -$19.75M | $2.85M | -$2.85M | $0 | $0 |
| Inventory | -$25.31M | $0 | $0 | $0 | $19.75M | -$2.85M | $2.85M | $0 | $0 |
| Accounts Payable | $26.61M | $1.51M | $2.78M | -$349K | $2.83M | -$735K | -$4.66M | $16.7M | $1.58M |
| Other Working Capital | $82.36M | $33.5M | -$13.05M | $13.26M | -$7.23M | $15.67M | -$6.26M | $5.79M | -$334K |
| Total Working Capital Change | -$51.06M | $32.04M | $5.06M | $28.08M | -$4.4M | $14.93M | -$10.91M | $22.49M | $1.24M |
| Other Non-Cash Items | $191.63M | -$111.3M | $103.93M | -$61.25M | $18.5M | $32.79M | $24.54M | $18.89M | $260K |
| Net Cash from Operating | -$445.91M | -$520.73M | -$527.72M | -$419.49M | -$497.93M | -$399.71M | -$253.59M | -$136.64M | -$40.49M |
| Investing Activities | |||||||||
| Capital Expenditures | -$1.1M | -$933K | -$1.31M | -$4.82M | -$48.25M | -$7.52M | -$5.14M | -$18.18M | -$464K |
| Acquisitions | $0 | -$140K | $0 | $0 | -$35M | $21.24M | -$5.49M | -$2.86M | $2.84M |
| Purchases of Investments | -$28.2M | -$88.4M | -$137.26M | -$193.06M | -$643.27M | -$287.85M | -$212.9M | $0 | $0 |
| Sales of Investments | $11M | $158.23M | $193.11M | $532.52M | $477.04M | $242.23M | $5.49M | $0 | $0 |
| Other Investing Activities | -$6.19M | -$7.97M | -$503K | $118.5M | $48.65M | -$21.09M | $784K | -$2.86M | $0 |
| Net Cash from Investing | -$24.49M | $60.78M | $54.03M | $453.15M | -$200.83M | -$52.99M | -$217.25M | -$21.04M | -$464K |
| Financing Activities | |||||||||
| Debt Repaid | -$385.5M | -$476.58M | - | $20.49M | -$1.08B | -$550M | -$36.94M | -$56.38M | -$4.13M |
| Common Stock Issuance | $34.15M | $314.74M | $449.81M | $4.85M | $0 | $0 | $366.24M | $95.54M | $107.16M |
| Common Stock Repurchases | -$48.28M | -$7.53M | -$6.88M | -$1.56M | -$204.75M | -$75.71M | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | -$997K | $0 | -$1.15M |
| Other Financing Activities | -$12.08M | -$35.34M | $8.61M | $4.06M | -$138.49M | -$27.1M | -$4.38M | $14.64M | $1.83M |
| Net Cash from Financing | $359.29M | $748.46M | $451.54M | -$13.13M | $736.45M | $447.19M | $398.79M | $501.55M | $112.98M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$111.1M | $288.51M | -$22.15M | $20.52M | $37.69M | -$5.52M | -$72.05M | $343.87M | $72.03M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$445.91M | -$520.73M | -$527.72M | -$419.49M | -$497.93M | -$399.71M | -$253.59M | -$136.64M | -$40.49M |
| Capital Expenditure | -$1.1M | -$933K | -$1.31M | -$6.32M | -$48.25M | -$7.52M | -$5.14M | -$18.18M | -$464K |
| Free Cash Flow | -$447.01M | -$521.66M | -$529.03M | -$425.81M | -$546.18M | -$407.23M | -$258.73M | -$154.82M | -$40.95M |
| Cash at Beginning | $683.24M | $394.73M | $416.88M | $396.37M | $358.68M | $364.2M | $436.25M | $92.38M | $20.34M |
| Cash at End | $572.14M | $683.24M | $394.73M | $416.88M | $396.37M | $358.68M | $364.2M | $436.25M | $92.38M |